vTv Therapeutics (VTVT) Total Liabilities (2014 - 2026)

vTv Therapeutics has disclosed Total Liabilities across 13 years of filings, most recently posting $8.9 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $8.9 million, down 61.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.9 million (down 61.72% YoY), and the FY2025 annual result was $25.5 million, up 6.25% from the prior year.
• Total Liabilities came in at $8.9 million for Q1 2026 at vTv Therapeutics, down from $25.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $29.6 million in Q2 2022 to a low of $8.9 million in Q1 2026.
• The 5-year median for Total Liabilities is $27.4 million (2022), against an average of $25.2 million.
• Across the five-year window, Total Liabilities jumped 233.11% in 2022 and sank 61.72% in 2026, its largest moves.
• vTv Therapeutics' Total Liabilities stood at $27.4 million in 2022, then gained by 7.91% to $29.6 million in 2023, then fell by 18.95% to $24.0 million in 2024, then advanced by 6.25% to $25.5 million in 2025, then plunged by 65.23% to $8.9 million in 2026.
• The last three Total Liabilities figures came in at $8.9 million (Q1 2026), $25.5 million (Q4 2025), and $29.0 million (Q3 2025), per Business Quant data.